Combined offering price of equity securities issued.

No definition available.

Name:	qnrx_CombinedOfferingPrice
Namespace Prefix:	qnrx_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Maximum payment of legal fees and out of pocket expenses paid by the entity to placement agent.

+ References

No definition available.

+ Details

Name:	qnrx_MaximumPaymentOfLegalFeesAndOutOfPocketExpensesToPlacementAgent
Namespace Prefix:	qnrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum threshold percentage of outstanding shares taken for consideration for non-exercise of warrants.

+ References

No definition available.

+ Details

Name:	qnrx_MinimumThresholdPercentageOfOutstandingSharesForNonExerciseOfWarrants
Namespace Prefix:	qnrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of aggregate gross proceeds paid as placement agent fees by the entity.

+ References

No definition available.

+ Details

Name:	qnrx_PlacementAgentFeesPercentageOfAggregateGrossProceeds
Namespace Prefix:	qnrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of warrants that are exercisable.

+ References

No definition available.

+ Details

Name:	qnrx_WarrantsExercisablePercentage
Namespace Prefix:	qnrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromWarrantExercises
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_StatementClassOfStockAxis=dei_AdrMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_December2024WarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_DirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesHWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_WarrantsExercisableTermFromClosingDateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_PublicAnnouncementForBaselineControlledPivotalStudiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesITrancheOneWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_PublicAnnouncementForMonotherapyPivotalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesITrancheTwoWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_PublicAnnouncementForAdjuvantPivotalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesJWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_PublicAnnouncementForAcceleratedOrTraditionalApprovalForTreatmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesKWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=qnrx_PublicAnnouncementForSaleOfPriorityReviewVoucherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_PreFundedWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=qnrx_SeriesIWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details) - USD ($)			3 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Oct. 14, 2025	Oct. 10, 2025	Mar. 31, 2024
Subsequent Event [Line Items]
Ordinary warrants			$ 5,482,472
ADSs
Subsequent Event [Line Items]
Number of shares issued for warrants			80,250
Subsequent Event \| December 2024 Warrants
Subsequent Event [Line Items]
Warrants gross proceeds	$ 3,300,000
Subsequent Event \| Private Placement
Subsequent Event [Line Items]
Private Placement		$ 16,600,000
Percentage of ordinary Shares outstanding		4.99%
Percentage of gross proceeds of private placement	7.00%
Legal fees and out of pocket expenses	$ 75,000
Net proceeds	$ 15,000,000
Subsequent Event \| Private Placement \| Director
Subsequent Event [Line Items]
Combined purchase price		$ 8.49
Ordinary warrants		$ 128,641
Subsequent Event \| Private Placement \| Series H warrants \| Warrants exercisable term from closing date \| Maximum
Subsequent Event [Line Items]
Warrants, term		5 years
Subsequent Event \| Private Placement \| Series H warrants \| Public announcement for baseline controlled pivotal studies
Subsequent Event [Line Items]
Warrants, term		30 days
Subsequent Event \| Private Placement \| Series I, tranche one warrants
Subsequent Event [Line Items]
Percentage of warrants exercisable		50.00%
Subsequent Event \| Private Placement \| Series I, tranche one warrants \| Warrants exercisable term from closing date \| Maximum
Subsequent Event [Line Items]
Warrants, term		5 years
Subsequent Event \| Private Placement \| Series I, tranche one warrants \| Public announcement for monotherapy pivotal trial
Subsequent Event [Line Items]
Warrants, term		30 days
Subsequent Event \| Private Placement \| Series I, tranche two warrants
Subsequent Event [Line Items]
Percentage of warrants exercisable		50.00%
Subsequent Event \| Private Placement \| Series I, tranche two warrants \| Maximum
Subsequent Event [Line Items]
Warrants, term		5 years
Subsequent Event \| Private Placement \| Series I, tranche two warrants \| Public announcement for adjuvant pivotal trial
Subsequent Event [Line Items]
Warrants, term		30 days
Subsequent Event \| Private Placement \| Series J warrants \| Warrants exercisable term from closing date \| Maximum
Subsequent Event [Line Items]
Warrants, term		5 years
Subsequent Event \| Private Placement \| Series J warrants \| Public announcement for accelerated or traditional approval for treatment
Subsequent Event [Line Items]
Warrants, term		30 days
Subsequent Event \| Private Placement \| Series K warrants \| Warrants exercisable term from closing date \| Maximum
Subsequent Event [Line Items]
Warrants, term		5 years
Subsequent Event \| Private Placement \| Series K warrants \| Public announcement for sale of priority review voucher
Subsequent Event [Line Items]
Warrants, term		30 days
Subsequent Event \| ADSs \| Private Placement
Subsequent Event [Line Items]
Number of shares issued for warrants		15,152
Subsequent Event \| ADSs \| Private Placement \| Director
Subsequent Event [Line Items]
Number of shares issued for warrants		15,152
Subsequent Event \| ADSs \| Private Placement \| Pre Funded Warrants
Subsequent Event [Line Items]
Number of ADS received for a warrant		1,993,939
Exercise price of warrants		$ 0.0001
Subsequent Event \| ADSs \| Private Placement \| Series H warrants
Subsequent Event [Line Items]
Exercise price of warrants		$ 9.075
Subsequent Event \| ADSs \| Private Placement \| Series H warrants \| Maximum
Subsequent Event [Line Items]
Number of shares issued for warrants		2,009,091
Subsequent Event \| ADSs \| Private Placement \| Series I warrants
Subsequent Event [Line Items]
Exercise price of warrants		$ 10.3125
Subsequent Event \| ADSs \| Private Placement \| Series I warrants \| Maximum
Subsequent Event [Line Items]
Number of shares issued for warrants		2,009,091
Subsequent Event \| ADSs \| Private Placement \| Series J warrants
Subsequent Event [Line Items]
Exercise price of warrants		$ 12.375
Subsequent Event \| ADSs \| Private Placement \| Series J warrants \| Maximum
Subsequent Event [Line Items]
Number of shares issued for warrants		2,009,091
Subsequent Event \| ADSs \| Private Placement \| Series K warrants
Subsequent Event [Line Items]
Exercise price of warrants		$ 12.375
Subsequent Event \| ADSs \| Private Placement \| Series K warrants \| Maximum
Subsequent Event [Line Items]
Number of shares issued for warrants		2,009,091